Oppenheimer raised the firm’s price target on Astria Therapeutics to $26 from $25 and keeps an Outperform rating on the shares. The firm notes that on Monday, Astria provided a Q2 business update highlighting recent clinical results in HAE for STAR-0215, now navenibart, and plans to advance into pivotal studies in Q1 2025, pending feedback from regulatory authorities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS: